Kovack Advisors Inc. Acquires 3,946 Shares of Moderna, Inc. (NASDAQ:MRNA)

Kovack Advisors Inc. lifted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 207.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,844 shares of the company’s stock after acquiring an additional 3,946 shares during the period. Kovack Advisors Inc.’s holdings in Moderna were worth $391,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Intrinsic Value Partners LLC boosted its stake in Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock valued at $3,435,000 after buying an additional 24,505 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Moderna by 11.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after acquiring an additional 167,596 shares during the last quarter. Vontobel Holding Ltd. grew its holdings in shares of Moderna by 148.2% in the third quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock valued at $7,758,000 after purchasing an additional 69,313 shares in the last quarter. Profund Advisors LLC increased its position in Moderna by 20.9% in the second quarter. Profund Advisors LLC now owns 56,218 shares of the company’s stock worth $6,676,000 after purchasing an additional 9,719 shares during the last quarter. Finally, Privium Fund Management B.V. raised its stake in Moderna by 74.0% during the third quarter. Privium Fund Management B.V. now owns 40,482 shares of the company’s stock valued at $2,705,000 after purchasing an additional 17,221 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In related news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders sold 2,930 shares of company stock worth $217,170. Company insiders own 15.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on MRNA. Royal Bank of Canada reiterated a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a research report on Thursday, September 19th. Barclays lowered their price objective on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research report on Friday, November 8th. Oppenheimer downgraded Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. UBS Group lowered their target price on Moderna from $140.00 to $108.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and lowered their price target for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Moderna currently has an average rating of “Hold” and an average target price of $93.18.

Moderna Stock Down 5.6 %

Shares of MRNA stock opened at $39.77 on Friday. Moderna, Inc. has a twelve month low of $38.76 and a twelve month high of $170.47. The stock has a 50 day moving average of $59.96 and a 200 day moving average of $97.80. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same period in the previous year, the firm earned ($1.39) EPS. The business’s quarterly revenue was up 3.8% on a year-over-year basis. On average, equities research analysts expect that Moderna, Inc. will post -9.43 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.